Meet Monica

A REAL GLAUCOMA PATIENT

After she was diagnosed with glaucoma, Monica started using eye drops to lower her IOP. She had trouble administering them at times and often forgot to use them. Later, her doctor suggested DURYSTA^®.

IOP=intraocular pressure.
Actual DURYSTA^® patient.

Three DURYSTA® patients standing together

Not actual DURYSTA^® patients.

Consistent Mean IOP Reduction Over Time¹

graphdot-icon1 DURYSTA^® 10 mcg (N=198)²

graphdot-icon2 Timolol 0.5% BID (N=198)²

Baseline at Hour 0: 24.6 mmHg

Up to 33% mean IOP reduction from baseline¹

graphdot-icon1 DURYSTA^® 10 mcg (N=198)²

graphdot-icon1 Timolol 0.5% BID (N=198)²

Baseline at Hour 0: 24.6 mmHg

Up to 33% mean IOP reduction from baseline¹

Mean IOP (mmHg)

graph-dot1 DURYSTA^® 10 mcg (N=176)²

graph-dot2 Timolol 0.5% BID (N=176)²

Baseline at Hour 0: 24.3 mmHg

Baseline at Hour 0: 24.5 mmHg

Up to 32% mean IOP reduction from baseline¹

graphdot-icon1 DURYSTA^® 10 mcg (N=176)²

graphdot-icon2 Timolol 0.5% BID (N=176)²

Baseline at Hour 0: 24.3 mmHg

Baseline at Hour 0: 24.5 mmHg

Up to 32% mean IOP reduction from baseline¹

Mean IOP (mmHg)

Study Design

A safety profile established in 2 clinical studies¹

MOST COMMON ADVERSE REACTIONS

Ocular

The most common ocular adverse reaction was conjunctival hyperemia, which occurred in 27% of patients.¹

Other common ocular adverse reactions reported in 5-10% of patients were foreign body sensation, eye pain, photophobia, conjunctival hemorrhage, dry eye, eye irritation, IOP increased, corneal endothelial cell loss, vision blurred, and iritis.¹

Ocular adverse reactions occurring in 1-5% of patients were anterior chamber cell, lacrimation increased, corneal edema, aqueous humor leakage, iris adhesions, ocular discomfort, corneal touch, iris hyperpigmentation, anterior chamber flare, anterior chamber inflammation, and macular edema.¹

Nonocular

The most common nonocular adverse event was headache, which was observed in 5% of patients.¹

You have options when ordering DURYSTA^®

FOR ORDERING

GO TO ALLERGAN DIRECT^™

Choose to order online with Allergan Direct through the buy-and-bill process—or acquire DURYSTA^® through a specialty pharmacy. The videos below provide introductions to each of these options.

Click to watch a video with an introduction to Buy and Bill for DURYSTA®

ORDERING DURYSTA^® ONLINE WITH ALLERGAN DIRECT

Allergan Direct offers a convenient experience with 24/7, on-demand flexibility. This solution allows you to place orders, pay invoices, and more.

Before ordering, you'll need to set up an Allergan Direct account by calling: 1-833-DURYSTA (1-833-387-9782)

Important

Call from 8 am to 8 pm ET

Have your practice contact information ready—including billing and shipping addresses—and your state license number

In order to run a credit check, we will need your business tax ID, bank name, account number, and contact information

If you already have an account for Allergan Direct, remember:

There is a minimum order quantity of 2

Orders arrive within 2 business days

New accounts receive an initial courtesy credit line of $20,000 while we process your credit application

HOW TO ORDER THROUGH A SPECIALTY PHARMACY

The benefits verification process will determine if your patient's insurance accommodates specialty pharmacy distribution

Allergan EyeCue^® will then help coordinate the specialty pharmacy experience

The specialty pharmacy contacts the patient to verify information and collect their copay

Next, your office receives DURYSTA^® from the specialty pharmacy and properly stores it

Finally, you administer DURYSTA^® to the patient when needed

Click to watch a video with an introduction to using a specialty pharmacy for DURYSTA®

Reimbursement support with Allergan EyeCue^®

FOR REIMBURSEMENT HELP

GO TO ALLERGAN EYECUE^®

YOUR COMPLETE RESOURCE FOR DURYSTA^® REIMBURSEMENT AND ACCESS

For your DURYSTA^® patients, through Allergan EyeCue^® you can:

Initiate a benefit verification

Request prior authorization support

Gain online access to case/patient management

Access information about billing, coding, and reimbursement support

Request specialty pharmacy enrollment

Request claims assistance and appeals support

Enroll in the DURYSTA^® Savings Program—eligible commercially-insured patients pay $0* for up to one implant per eye

Submit claims for reimbursement under the DURYSTA^® Savings Program

Before you can begin taking advantage of this resource for ongoing DURYSTA^® support, an Allergan EyeCue^® account is required. Details are available at the Allergan EyeCue^® site.

Offer valid only for commercially-insured patients with plans covering DURYSTA^®; patient out-of-pocket expense may vary. Offer not valid for patients receiving reimbursement from Medicare, Medicaid, or any other federal, state, or government-funded healthcare program. See Program Terms, Conditions, and Eligibility Criteria here or visit www.durystasavingsprogram.com.

The DURYSTA^® Physician Training Portal

FOR ADMINISTRATION HELP

VISIT THE TRAINING PORTAL

DESIGNED TO INTRODUCE YOU TO THE IMPLANT DELIVERY DIRECTIONS FOR DURYSTA^®

The Physician Training Portal provides:

An overview of the drug delivery system and mechanism of action

A video series featuring Paul Singh, MD, with insights on patient selection, patient discussion, and administration

Demonstrations of correct administration technique

Examples of typical implant behavior following administration

A guide through various troubleshooting scenarios

Downloadable resources and supplements from Cataract & Refractive Surgery Today

Physician Administration Guide

A complete reference for the DURYSTA^® administration procedure

DOWNLOAD

Download materials and resources for your practice and your patients

For Your Practice

ORDERING

How to Order Flashcard

A handy reference to consult when ordering DURYSTA^®

REIMBURSEMENT

Patient Enrollment Form

Quickly enroll patients in Allergan EyeCue^® to begin taking advantage of the available resources

Billing and Coding Guide

A brief overview of billing and coding information for DURYSTA^®

ADDITIONAL RESOURCES

Buy-and-Bill/Specialty Pharmacy Flashcard

DURYSTA^® Savings Program Flashcard for Offices

Allergan EyeCue^® Overview

DURYSTA^® Savings Program
Reimbursement Request Form

DURYSTA^® Procedure Consent Form

Sample CMS-1500 Form

Sample ASC CMS-1500 Form

Sample UB-04 Form

For Your Patients

DURYSTA® Patient In-Office Screener and Checklist

DURYSTA^® In-Office Patient Screener

A tool to help identify patients who might be potential candidates for DURYSTA^®

DURYSTA® Patient Savings Program Flashcard

DURYSTA^® Savings Program Patient Flashcard

All the information eligible patients need to enroll and begin saving on their DURYSTA^® prescription costs

INDICATIONS AND USAGE

DURYSTA^® (bimatoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).

IMPORTANT SAFETY INFORMATION

Contraindications

DURYSTA^® is contraindicated in patients with: active or suspected ocular or periocular infections; corneal endothelial cell dystrophy (e.g., Fuchs’ Dystrophy); prior corneal transplantation or endothelial cell transplants (e.g., Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK]); absent or ruptured posterior lens capsule, due to the risk of implant migration into the posterior segment; hypersensitivity to bimatoprost or to any other components of the product.

Warnings and Precautions

The presence of DURYSTA^® implants has been associated with corneal adverse reactions and increased risk of corneal endothelial cell loss. Administration of DURYSTA^® should be limited to a single implant per eye without retreatment. Caution should be used when prescribing DURYSTA^® in patients with limited corneal endothelial cell reserve.

DURYSTA^® should be used with caution in patients with narrow iridocorneal angles (Shaffer grade < 3) or anatomical obstruction (e.g., scarring) that may prohibit settling in the inferior angle.

Macular edema, including cystoid macular edema, has been reported during treatment with ophthalmic bimatoprost, including DURYSTA^® intracameral implant. DURYSTA^® should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

Prostaglandin analogs, including DURYSTA^®, have been reported to cause intraocular inflammation. DURYSTA^® should be used with caution in patients with active intraocular inflammation (e.g., uveitis) because the inflammation may be exacerbated.

Ophthalmic bimatoprost, including DURYSTA^® intracameral implant, has been reported to cause changes to pigmented tissues, such as increased pigmentation of the iris. Pigmentation of the iris is likely to be permanent. Patients who receive treatment should be informed of the possibility of increased pigmentation. While treatment with DURYSTA^® can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.

Intraocular surgical procedures and injections have been associated with endophthalmitis. Proper aseptic technique must always be used with administering DURYSTA^®, and patients should be monitored following the administration.

Adverse Reactions

In controlled studies, the most common ocular adverse reaction reported by 27% of patients was conjunctival hyperemia. Other common adverse reactions reported in 5%-10% of patients were foreign body sensation, eye pain, photophobia, conjunctival hemorrhage, dry eye, eye irritation, intraocular pressure increased, corneal endothelial cell loss, vision blurred, iritis, and headache.

Please see full Prescribing Information.

References: 1. DURYSTA^® [Prescribing Information]. Irvine, CA: Allergan, Inc.; 2020. 2. Data on file, Allergan, 2020. 3. Standring S. Orbit and accessory visual apparatus. In: Gray’s Anatomy: The Anatomical Basis of Clinical Practice. 41st ed. Philadelphia, PA: Elsevier Limited; 2016:666-708. 4. DURYSTA^® NDA FDA Approval Letter. March 4, 2020.

IMPORTANT SAFETY INFORMATION AND INDICATIONS AND USAGE
COLLAPSE

Contraindications

Warnings and Precautions

DURYSTA^® should be used with caution in patients with narrow iridocorneal angles (Shaffer grade < 3) or anatomical obstruction (e.g., scarring) that may prohibit settling in the inferior angle.

Adverse Reactions